November 18, 2026
Health news, explained with evidence
LIVE
CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Recall Issued for Generic Propranolol Over Potential Metal Contamination Understanding Food Science: Why Some Leftovers Freeze Better Than Others Could an mRNA Vaccine Help Treat Acne? AI-Generated Hospital Discharge Summaries Outperform Human Versions in Clinical Study FDA Leadership Uncertainty Follows Withdrawal of Commissioner Nominee CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Recall Issued for Generic Propranolol Over Potential Metal Contamination Understanding Food Science: Why Some Leftovers Freeze Better Than Others Could an mRNA Vaccine Help Treat Acne? AI-Generated Hospital Discharge Summaries Outperform Human Versions in Clinical Study FDA Leadership Uncertainty Follows Withdrawal of Commissioner Nominee

FDA Approves Adrabetadex for Rare Infantile-Onset Niemann-Pick Disease Type C

❤️ Conditions & Care 2 min read 👁 1

The FDA has approved adrabetadex to treat infantile-onset Niemann-Pick disease type C, a rare and fatal genetic condition characterized by the buildup of cholesterol in brain cells.

FDA Approves Adrabetadex for Rare Infantile-Onset Niemann-Pick Disease Type C❤️Conditions & Care

Photo: medpagetoday.com

Key points

  • Adrabetadex is approved for infantile-onset Niemann-Pick disease type C.
  • Clinical data showed a 55% reduction in the risk of death.
  • The drug carries a boxed warning for potential permanent hearing loss.

The FDA has granted approval for adrabetadex (Lembaz), an injectable treatment designed for patients with infantile-onset Niemann-Pick disease type C (NPC). The therapy is indicated for both children and adults weighing at least 15 pounds who began showing neurological symptoms before the age of 6. By targeting cholesterol accumulation within brain cells, the drug aims to slow the progressive neurological decline associated with this rare lysosomal storage disorder.

Clinical data supporting the approval, derived from 36 patients across three studies and an expanded access program, indicated a 55% reduction in the risk of mortality compared to matched external controls. Patients receiving the treatment showed a median overall survival of 8.5 years, compared to 4.9 years in the control group. These benefits were observed regardless of whether patients were concurrently using miglustat, an off-label therapy for the condition.

What to know:

  • Adrabetadex is administered via intrathecal injection every two weeks by a trained healthcare provider.
  • Common side effects include fatigue, ataxia, vomiting, and nausea.
  • The medication carries a boxed warning for potential permanent hearing loss, necessitating regular hearing evaluations before and during treatment.
Early diagnosis and prompt treatment are critical because neurological function that is lost cannot be regained, said study investigator Elizabeth Berry-Kravis, MD, PhD.

As with all medical treatments, patients and caregivers should consult with a healthcare professional to discuss the risks, benefits, and suitability of this therapy for their specific medical history. The efficacy data, while promising, is based on a small cohort of 36 patients, and long-term monitoring remains essential.

Source medpagetoday.com — medpagetoday.com/genetics/generalgenetics/123945 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.